Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

Numerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High-grade serous (HGS) carcinoma is the most clinically important histological subtype of ovarian cancer. As these tumours may arise from the ovary, Fallopian tube or peritoneum, they are collectively referred to as high-grade pelvic serous carcinoma (HGPSC). To identify the true prevalence of TP53 mutations in HGPSC, we sequenced exons 2-11 and intron-exon boundaries in tumour DNA from 145 patients. HGPSC cases were defined as having histological grade 2 or 3 and FIGO stage III or…

• CR
  Cancer Research UK
• NI
  National Institute for Health and Care Research
• UO
  University of Cambridge
• MR
  Medical Research Council
• NH
  National Health and Medical Research Council
• CC
  Cancer Council South Australia
• CC
  Cancer Council Victoria
• CC
  Cancer Council NSW
• CC
  Cancer Council Tasmania
• CC
  Cancer Council Western Australia
• NC
  NIHR Cambridge Biomedical Research Centre